Winrevair (sotatercept-csrk) / BMS, Merck (MSD) 
Welcome,         Profile    Billing    Logout  
 16 Diseases   13 Trials   13 Trials   579 News 
16 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Winrevair (sotatercept-csrk) / BMS, Merck (MSD)
NCT06409026: Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension

Recruiting
4
21
US
Sotatercept
Mayo Clinic
Pulmonary Arterial Hypertension
02/25
02/25
RECOMPENSE, NCT06658522: Right Ventricular Compensation with Sotatercept: a Prospective Single Arm Open Label Phase 4 Study to Evaluate the Effects of Sotatercept on Right Ventricular Function in Pulmonary Arterial Hypertension

Not yet recruiting
4
20
NA
Sotatercept
Amsterdam UMC, location VUmc, MSD Nederland BV
Pulmonary Arterial Hypertension PAH, Pulmonary Arterial Hypertension WHO Group I, Pulmonary Arterial Hypertension
10/26
10/26
2021-001498-21: A study to evaluate Sotatercept in Participants with PAH WHO FC III or FC IV at High Risk of Mortality Estudio para evaluar sotatercept en pacientes con HAP con una CF de la OMS III o IV y riesgo elevado de mortalidad

Not yet recruiting
3
166
Europe
Sotatercept, ACE-011, Lyophilisate for solution for injection
Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Pulmonary Arterial Hypertension (PAH) Hipertensión Arterial Pulmonar (HAP), Cardiovascular Disease Enfermedad Cardiovascular, Diseases [C] - Cardiovascular Diseases [C14]
 
 
MK-7962-020, NCT05818137: A Study of Sotatercept in Japanese Pulmonary Arterial Hypertension (PAH) Participants

Active, not recruiting
3
46
Japan
Sotatercept, MK-7962, ActRIIA-IgG1Fc, ACE-011
Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
03/24
08/25
ZENITH, NCT04896008: A Study of Sotatercept in Participants With PAH WHO FC III or FC IV at High Risk of Mortality (MK-7962-006/)

Active, not recruiting
3
172
Europe, Canada, US, RoW
Sotatercept, MK-7962, ACE-011, Placebo
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
07/24
02/25
SOTERIA, NCT04796337 / 2020-005061-13: A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12)

Recruiting
3
700
Europe, Canada, US, RoW
Sotatercept, ACE-011, MK-7962
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension, PAH
02/31
02/31
HYPERION, NCT04811092 / 2021-000199-12: Study of Sotatercept in Newly Diagnosed Intermediate- and High-Risk PAH Participants (MK-7962-005/A011-13)

Recruiting
3
444
Europe, Canada, US, RoW
Sotatercept, MK-7962, ACE-011, Placebo
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Pulmonary Arterial Hypertension
08/26
12/29
2022-000478-25: Sotatercept in Children with Pulmonary Artery Hypertension on Standard of Care

Ongoing
2
42
Europe
Sotatercept, MK-7962, Lyophilisate for solution for injection
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pulmonary arterial hypertension, Pulmonary arterial hypertension (PAH) is a rare, progressive disorder characterized by high blood pressure (hypertension) in the arteries of the lungs, Diseases [C] - Respiratory Tract Diseases [C08]
 
 
2021-003020-32: A Phase 2 Study of Sotatercept for Combined Postcapillary and Precapillary Pulmonary Hypertension Treatment

Not yet recruiting
2
180
Europe
Sotatercept, ACE-011 / MK-7962, Lyophilisate for solution for injection
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., ACCELERON PHARMA INC., Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA, Acceleron Pharma Inc., Acceleron Pharma Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA
Combined Postcapillary and Precapillary Pulmonary Hypertension (Cpc-PH) due to Heart Failure with Preserved EjectionFraction (HFpEF), Combined Postcapillary and Precapillary Pulmonary Hypertension due to Heart Failure, Diseases [C] - Cardiovascular Diseases [C14]
 
 
CADENCE, NCT04945460: A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

Recruiting
2
150
Europe, Canada, US, RoW
Sotatercept 0.3 mg/kg, ACE-011, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Hypertension, Pulmonary
10/25
02/27
LIGHTRAY, NCT06664801: A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

Recruiting
2
160
Europe, US, RoW
Sotatercept, MK-7962, Background PAH Therapy
Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
07/26
07/26
Sox-PH, NCT06351345: 129 Xenon Imaging in Patients Treated with Sotatercept

Not yet recruiting
2
14
US
129Xe Hyperpolarized
Bastiaan Driehuys, Merck Sharp & Dohme LLC
Pulmonary Hypertension, Pulmonary Arterial Hypertension
08/25
08/25
MOONBEAM, NCT05587712 / 2022-000478-25: Study to Evaluate Sotatercept (MK-7962) in Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-008)

Recruiting
2
42
Europe, US, RoW
Sotatercept, MK-7962
Merck Sharp & Dohme LLC, Merck Sharp & Dohme LLC
Pulmonary Arterial Hypertension
09/28
09/28
NCT01562405: Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, not recruiting
1
33
US
ACE-011, Sotatercept, Lenalidomide, Revlimid, Dexamethasone, Decadron, Pomalidomide, Pomalyst
Massachusetts General Hospital, Multiple Myeloma Research Consortium
Multiple Myeloma
12/24
06/25
NCT03724227: Expanded Access for ACE-011

No Longer Available
N/A
US
ACE-011, Sotatercept
Celgene
Myelodysplastic Syndrome
 
 
NCT06751082: A Study of Sotatercept for Pulmonary Hypertension

Not yet recruiting
N/A
120
US
Mayo Clinic
Pulmonary Hypertension
01/35
01/35

Download Options